Ariad to Resume Sales of Iclusig
Ariad Pharmaceuticals Inc. will be resuming sales for its leukemia drug, Iclusig, after it was suspended from the U.S. market for blood clot concerns.
Iclusig Linked to Blood Clots
- Iclusig (ponatinib) was approved last December by the U.S. Food and Drug Administration as part of an accelerated approval process based on a single clinical trial demonstrating a positive patient response.
- However, post marketing trials showed that patients were at much higher risk of suffering serious side effects including blood clots and heart damage.
- Ariad announced on December 20, 2013 that sales for Iclusig would resume, but the drug will require an updated boxed warning detailing the new blood clot and cardiovascular problems.
Side Effects of Iclusig
According to Drugs.com may lead to:
- Irregular Heart Beat
- Cardiac Arrest
- Decreased Vision
- Loss of blood flow resulting in tissue death and amputation
- Heart Failure
- Respiratory Infection
- Blood Clots
- Heart Attack
Contact an Experienced Product Liability Attorney
Thomas J. Henry are leaders in the area of drug and product liability litigation. Our Defective Drug and Products Division have extensive knowledge and resources in order to represent our clients efficiently and aggressively. The Defective Drug and Products Division represent a multitude of people who are battling against manufacturers of medical devices and/ or defective pharmaceuticals.
If you or a loved one have been injured by or have developed serious side-effects from the use of defective medications or medical devices, contact Thomas J. Henry immediately. We represent clients/victims all over the country. We are available 24/7, nights and weekends.